Search For "bharat biotech"
SEC asks for more data to grant full market approval to Covaxin and Covish
Updated : 4 years, 2 months ago IST
New Delhi [India], January 14 (ANI): The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) will continue thorough review of data submitted by the Serum Institute of India (SII) and Bharat Biotech for granting full market approval to Covaxin and Covishield, sources
Read More
DCGI's SEC to review applications of Bharat Biotech, SII for full market a
Updated : 4 years, 2 months ago IST
New Delhi [India], January 14 (ANI): Drugs Controller General of India (DCGI)'s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said.
Read More
COVID-19 vaccine Covaxin now universal vaccine for adults, children: Bhara
Updated : 4 years, 2 months ago IST
New Delhi [India], January 14 (ANI): Hyderabad-based vaccine manufacturer Bharat Biotech on Thursday announced that its indigenously developed COVID-19 vaccine Coavaxin is now a universal vaccine for adults and children.
Read More
Covaxin can neutralise Delta, Omicron variants of coronavirus: Bharat Biot
Updated : 4 years, 2 months ago IST
New Delhi [India], January 12 (ANI): Hyderabad-based Bharat Biotech on Wednesday claimed that its COVID vaccine Covaxin can neutralise both Delta and Omicron variants of coronavirus.
Read More
COVAXIN booster dose trial demonstrates long-term safety with no serious a
Updated : 4 years, 2 months ago IST
New Delhi [India], January 8 (ANI): Covaxin manufacture Bharat Biotech on Saturday said that the booster dose trials have shown "promising results" of long-term safety with "no serious adverse events".
Read More
COVID-19: Bharat Biotech urges healthcare workers to ensure administration
Updated : 4 years, 2 months ago IST
Hyderabad (Telangana) [India], January 8 (ANI): Hyderabad-based vaccine manufacturer Bharat Biotech on Friday said that it has received reports of COVID-19 vaccines other than Covaxin are being administered in children of age group 15-18 years in the country and urged healthcare workers t
Read More
No paracetamol or pain killers are recommended after being vaccinated with
Updated : 4 years, 2 months ago IST
New Delhi [India], January 5 (ANI): Hyderabad-based vaccine manufacturer Bharat Biotech on Wednesday said that no paracetamol or pain killers are recommended after being vaccinated with COVID-19 vaccine Covaxin.
Read More
Bharat Biotech gets SEC approval for phase 3 clinical trials of COVID boos
Updated : 4 years, 2 months ago IST
New Delhi [India], January 5 (ANI): The Subject Experts Committee (SEC) of the Drug Controller General of India (DCGI) on Wednesday granted approval to Bharat Biotech for conducting intranasal phase 3 trials and heterologous trials for COVID-19 booster intranasal vaccine for those who hav
Read More
SEC to hold meeting on Bharat Biotech's Nasal vaccine booster dose
Updated : 4 years, 2 months ago IST
New Delhi [India], January 4 (ANI): The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) is expected to meet on Tuesday afternoon to discuss Bharat Biotech's application for clinical trials of its intranasal Covid vaccine as a booster or a third dose.
Read More
COVID-19: India supplies 5 lakh more Covaxin doses to Afghanistan
Updated : 4 years, 2 months ago IST
New Delhi [India], January 3 (ANI): Bharat Biotech on Monday informed that India has supplied another batch of humanitarian assistance consisting of 5,00,000 doses of COVID-19 vaccine, Covaxin to Afghanistan.
Read More
Covaxin found to be safe, immunogenic in 2-18 age group in phase 2, 3 stud
Updated : 4 years, 2 months ago IST
Hyderabad (Telangana) [India], December 30 (ANI): Hyderabad based vaccine manufacturer Bharat Biotech on Thursday announced that Covaxin (BBV152) has been found to be "safe, well-tolerated, and immunogenic" in the age group of 2-18 years in phase II/III study, said a company's statement.
Read More
Proven record for safety, says Bharat Biotech after Covaxin gets emergency
Updated : 4 years, 3 months ago IST
New Delhi [India], December 25 (ANI): Covaxin has a proven record for safety and efficacy from all the variants of COVID-19, said Bharat Biotech after its vaccine received emergency usage approval from the Drugs Controller General of India (DCGI) for kids aged between 12-18 years.
Read More